ELVN Chief Medical Officer Collins Sells $192K of Stock
Key Points
- Chief Medical Officer Helen Louise Collins sold 5,000 shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) for $192,342 on October 19, 2026, under a pre-arranged plan.
- After the trade, Helen Louise Collins holds 25,000 $ELVN shares, down 16.67% from before the trade.
- The clinical-stage biotech firm trades around $41.25, up 10.5% since closing at $37.32 on October 16, with its next earnings report scheduled for November 11, 2026.
- Wall Street firms including HC Wainwright & Co. and JP Morgan recently updated coverage, setting price targets reaching up to $78.
Since the trade, $ELVN is up 8.1% to date (from the $38.70 close on Oct 19, 2026).
Get Enliven Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $ELVN.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Enliven Therapeutics, Inc. alert may contain errors. Disclosures
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Chief Medical Officer Helen Louise Collins sold 5,000 shares of the company on October 19, 2026. The transaction was detailed in a Form 4 filing with the SEC. The sale was carried out under a pre-arranged trading plan.
ELVN
Enliven Therapeutics, Inc.
Inside Helen Louise Collins's Enliven Therapeutics Trade
Collins sold the shares at a price of $38.47 each, bringing the total value of the transaction to $192,342. Following the sale, she holds 25,000 shares of the biotech firm. This marks a 16.67% reduction in her direct share ownership.
Other Institutional Activity in Enliven Therapeutics
Baker Bros. Advisors grew its holdings by 633,785 shares, ending with 905,191 shares worth about $45,938,443.25. Orbimed Advisors LLC. reduced its stake by 1,182,767 shares, leaving it with 6,776,632 shares valued at approximately $283,398,748. Polar Capital Holdings PLC added 1,364,750 shares for a 26.9% increase, finishing with 6,430,636 shares worth about $268,929,195. Vestal Point Capital, LP grew its holdings by 750,081 shares, ending with 4,000,000 shares valued at roughly $167,279,998. Commodore Capital Lp kept its stake steady with 3,275,000 shares worth about $136,960,499.
Enliven Therapeutics, Inc. Stock Down 16.6%
The stock recently traded around $41.25 as of October 21, 2026. That is up about 10.5% since it closed at $37.32 on October 16, 2026.
Recent Earnings
The company reported trailing twelve month earnings per share of -$1.65, a return on equity of -15.3%, and a net margin of 0.0%. The next quarterly report is set for November 11, 2026.
Insider Buying and Selling at Enliven Therapeutics, Inc.
Prior to this transaction, Collins sold 5,000 shares on August 17, 2026, for $292,931, and another 5,000 shares on September 17, 2026, for $251,754. Chief Financial Officer Benjamin Hohl sold 6,018 shares on September 17, 2026, for $303,003. Director J Scott Garland sold 13,000 shares at $46.67 on October 1, 2026, for $606,719.
Analysts Set New Price Targets
On August 18, 2026, William Blair initiated coverage with an Outperform rating. On the same day, Barclays initiated coverage with an Overweight rating and a $78 price target. JP Morgan initiated coverage with an Overweight rating and a $75 price target on October 1, 2026. Morgan Stanley followed on October 2, 2026, initiating coverage with an Overweight rating and a $70 price target. HC Wainwright & Co. maintained a Buy rating and raised its target from $65 to $73 on October 19, 2026.
About Enliven Therapeutics
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boulder, Colorado. The firm focuses on discovering and developing small molecule inhibitors to assist cancer patients. This insider transaction follows recent institutional portfolio adjustments and ongoing analyst coverage as the company advances its clinical pipeline toward its next earnings update.
Bottom Line
Investors will look toward the upcoming earnings release on November 11, 2026, for further updates on the company's financial and clinical progress. Form 4 filings will continue to show how executives manage their holdings over time.
Related Filing Alerts
Source: Helen Louise Collins's Form 4 filing on $ELVN (Oct 19, 2026). Written by software, not financial advice. How we make alerts